Patents Assigned to Infinity Pharmaceuticals, Inc.
  • TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS
    Publication number: 20140120083
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 1, 2014
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Howard M. STERN, Jeffery L. KUTOK
  • INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    Publication number: 20140121183
    Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.
    Type: Application
    Filed: December 20, 2013
    Publication date: May 1, 2014
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Julian ADAMS, Mark L. Behnke, Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Tao Liu, Daniel A. Snyder, Thomas T. Tibbitts
  • TREATMENT OF RHEUMATOID ARTHRITIS AND ASTHMA USING PI3 KINASE INHIBITORS
    Publication number: 20140120060
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating rheumatoid arthritis or asthma.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 1, 2014
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Vito J. Palombella, Jeffrey L. Kutok
  • Analogs of benzoquinone-containing ansamycins and methods of use thereof
    Patent number: 8703755
    Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.
    Type: Grant
    Filed: August 20, 2012
    Date of Patent: April 22, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Julian Adams, Yun Gao, Asimina T. Georges Evangelinos, Louis Grenier, Roger H. Pak, James R. Porter, James L. Wright
  • Enzymatic transamination of cyclopamine analogs
    Patent number: 8703448
    Abstract: The invention relates to the preparation of amino-cyclopamines by the enzymatic transamination of a corresponding keto-cyclopamines in the presence of a cofactor and an amino donor.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: April 22, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian C. Austad, Adilah Bahadoor, Jitendra D. Belani, Somarajannair Janardanannair, Charles W. Johannes, Gregg F. Keaney, Priscilla L. White, Sheldon L. Wallerstein
  • METHODS OF USE OF CYCLOPAMINE ANALOGS
    Publication number: 20140107142
    Abstract: The invention provides methods for treating various conditions using derivatives of cyclopamine having the following formula:
    Type: Application
    Filed: October 15, 2013
    Publication date: April 17, 2014
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Karen J. McGovern, Martin R. Tremblay, William Matsui
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20140100214
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 10, 2014
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. CASTRO, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Tao Liu, Daniel A. Snyder, Martin R. Tremblay, Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan
  • CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION
    Publication number: 20140088099
    Abstract: Chemical compounds that modulate kinase activity, including PI3 kinase activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 27, 2014
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda REN, Yi Liu, Liansheng Li, Katrina Chan, Alfredo C. Castro, Catherine A. Evans
  • TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE
    Publication number: 20140079667
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: August 23, 2013
    Publication date: March 20, 2014
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah BAHADOOR, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Cyclopamine analogs
    Patent number: 8669365
    Abstract: The invention provides novel derivatives of cyclopamine having the following formula:
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: March 11, 2014
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, André B. Charette, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Martin Tremblay
  • INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    Publication number: 20130345173
    Abstract: Provided herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2, R3, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating FAAH-mediated disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.
    Type: Application
    Filed: August 23, 2013
    Publication date: December 26, 2013
    Applicant: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Daniel A. Snyder
  • TREATMENT OF LUPUS, FIBROTIC CONDITIONS, AND INFLAMMATORY MYOPATHIES AND OTHER DISORDERS USING PI3 KINASE INHIBITORS
    Publication number: 20130344061
    Abstract: Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating lupus, a fibrotic condition, or inflammatory myopathies and other conditions (e.g., skin conditions).
    Type: Application
    Filed: March 15, 2013
    Publication date: December 26, 2013
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Vito J. PALOMBELLA, David G. WINKLER
  • INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    Publication number: 20130338107
    Abstract: Provided herein are compounds of formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3, R4, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating an FAAH-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.
    Type: Application
    Filed: August 19, 2013
    Publication date: December 19, 2013
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan
  • Chemical compounds, compositions and methods for kinase modulation
    Patent number: 8604032
    Abstract: Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, and methods of use thereof The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: December 10, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Alfredo C. Castro, Catherine A. Evans
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20130267521
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 10, 2013
    Applicants: Intellikine LLC, Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. CASTRO, Katrina CHAN, Catherine A. EVANS, Somarajannair JANARDANANNAIR, Andre LESCARBEAU, Liansheng LI, Tao LIU, Yi LIU, Pingda REN, Daniel A. SNYDER, Martin R. TREMBLAY
  • Inhibitors of fatty acid amide hydrolase
    Patent number: 8546564
    Abstract: Provided herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating FAAH-mediated disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: October 1, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Michael J. Grogan, Daniel A. Snyder
  • Tetrazolones as inhibitors of fatty acid synthase
    Patent number: 8546432
    Abstract: Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: October 1, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Adilah Bahadoor, Alfredo C. Castro, Lawrence K. Chan, Gregg F. Keaney, Marta Nevalainen, Vesa Nevalainen, Stephane Peluso, Daniel A. Snyder, Thomas T. Tibbitts
  • Inhibitors of fatty acid amide hydrolase
    Patent number: 8541581
    Abstract: Provided herein are compounds of formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2, R3, R4, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating an FAAH-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: September 24, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan
  • TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE
    Publication number: 20130243727
    Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
    Type: Application
    Filed: April 29, 2013
    Publication date: September 19, 2013
    Applicant: INFINITY PHARMACEUTICALS, INC.
    Inventors: Adilah BAHADOOR, Alfredo C. CASTRO, Lawrence K. CHAN, Gregg F. KEANEY, Marta NEVALAINEN, Vesa NEVALAINEN, Stephane PELUSO, Thomas T. TIBBITTS
  • Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
    Patent number: 8461191
    Abstract: One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: June 11, 2013
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Edward B. Holson, Brian T. Hopkins, Nii O. Koney, Daniel A. Snyder, Thomas T. Tibbitts